Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. Among authors: pignata s. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. Colombo N, et al. Among authors: pignata s. Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062. Ann Oncol. 2019. PMID: 31046081 Free article.
Unilateral post-chemotherapy robot-assisted retroperitoneal lymph node dissection in Stage II non-seminomatous germ cell tumor: A tertiary care experience.
Franzese D, Tufano A, Izzo A, Muscariello R, Grimaldi G, Quarto G, Castaldo L, Rossetti S, Pandolfo SD, Desicato S, Del Prete P, Ferro M, Pignata S, Perdonà S. Franzese D, et al. Among authors: pignata s. Asian J Urol. 2023 Oct;10(4):440-445. doi: 10.1016/j.ajur.2023.05.002. Epub 2023 Jul 25. Asian J Urol. 2023. PMID: 38024429 Free PMC article.
Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group.
Malapelle U, Donne AD, Pagni F, Fraggetta F, Rocco EG, Pasello G, Perrone G, Pepe F, Vatrano S, Pignata S, Pinto C, Pruneri G, Russo A, Soto Parra HJ, Vallone S, Marchetti A, Troncone G, Novello S. Malapelle U, et al. Among authors: pignata s. Crit Rev Oncol Hematol. 2024 Jan;193:104217. doi: 10.1016/j.critrevonc.2023.104217. Epub 2023 Nov 30. Crit Rev Oncol Hematol. 2024. PMID: 38040072 Free article. Review.
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways.
Pastò B, Buzzatti G, Schettino C, Malapelle U, Bergamini A, De Angelis C, Musacchio L, Dieci MV, Kuhn E, Lambertini M, Passarelli A, Toss A, Farolfi A, Roncato R, Capoluongo E, Vida R, Pignata S, Callari M, Baldassarre G, Bartoletti M, Gerratana L, Puglisi F. Pastò B, et al. Among authors: pignata s. Crit Rev Oncol Hematol. 2024 May 7;199:104379. doi: 10.1016/j.critrevonc.2024.104379. Online ahead of print. Crit Rev Oncol Hematol. 2024. PMID: 38718940 Free article. Review.
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
Roma C, Esposito Abate R, Sacco A, Califano D, Arenare L, Bergantino F, Pisano C, Cecere SC, Scambia G, Lorusso D, Artioli G, Tasca G, Spina A, Russo D, Gadducci A, De Angelis C, Bologna A, Marchini S, Capoluongo ED, Perrone F, Pignata S, Normanno N. Roma C, et al. Among authors: pignata s. Eur J Cancer. 2024 May 23;206:114127. doi: 10.1016/j.ejca.2024.114127. Online ahead of print. Eur J Cancer. 2024. PMID: 38797038
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.
Santagata S, Rea G, Bello AM, Capiluongo A, Napolitano M, Desicato S, Fragale A, D'Alterio C, Trotta AM, Ieranò C, Portella L, Persico F, Di Napoli M, Di Maro S, Feroce F, Azzaro R, Gabriele L, Longo N, Pignata S, Perdonà S, Scala S. Santagata S, et al. Among authors: pignata s. Br J Cancer. 2024 May 4. doi: 10.1038/s41416-024-02702-x. Online ahead of print. Br J Cancer. 2024. PMID: 38704478
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
Pignata S, Califano D, Lorusso D, Arenare L, Bartoletti M, De Giorgi U, Andreetta C, Pisano C, Scambia G, Lombardi D, Farolfi A, Cinieri S, Passarelli A, Salutari V, De Angelis C, Mignogna C, Priolo D, Capoluongo ED, Tamberi S, Scaglione GL, Arcangeli V, De Cecio R, Scognamiglio G, Greco F, Spina A, Turinetto M, Russo D, Carbone V, Casartelli C, Schettino C, Perrone F. Pignata S, et al. Ann Oncol. 2024 May 3:S0923-7534(24)00128-5. doi: 10.1016/j.annonc.2024.04.007. Online ahead of print. Ann Oncol. 2024. PMID: 38704093
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
453 results